TC Biopharm: Difference between revisions
>Chris Created page with "TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candida..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
== Summary == | |||
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. | TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. | ||
__INDEX__ | |||
Latest revision as of 19:30, 20 August 2022
Summary edit edit source
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.